Poplar Therapeutics

Developer of anti-IgE therapy for allergic disease treatment

placeBoston, Massachusetts, United States calendar_todayFounded 2020 language poplartx.com

Innovation

2 patent families — focus: Chemistry & metallurgy; filing pace active.

YearFilings
20241
20261

Investor mix

6 investors on record; lead investors include SR One, Vida Ventures, Platanus, Janus Henderson Investors.

Investor typeCountShare
Venture capital350%
Other / undisclosed350%
Coming soon